Chimeric Therapeutics Ltd. (AU:CHM) has released an update.
Chimeric Therapeutics Limited reports a significant reduction in its annual loss, down 51.7% to $12,529,849 for the fiscal year ending on 30 June 2024, compared to the previous year. The decrease in losses is attributed to a decrease in staff, lower general and administrative expenses, and a strategic reprioritization of projects. Despite the loss, the company’s cash reserves have increased, indicating a strengthened financial position.
For further insights into AU:CHM stock, check out TipRanks’ Stock Analysis page.
